News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
US FDA Objects to Dendreon Corporation Promotions for Provenge
August 9, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Dendreon Corp exaggerated the benefits of its novel prostate cancer vaccine and downplayed risks in some sales materials for the product, U.S. regulators said in a letter released on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Approvals
Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug
March 30, 2026
·
3 min read
·
Tristan Manalac
Government
After Speaking out of Turn, Malone Steps Down From Vaccine Committee
March 27, 2026
·
2 min read
·
Tristan Manalac
Gene therapy
Rocket’s Gene Therapy Wins FDA Greenlight, Clearing Way for Future Products
March 27, 2026
·
2 min read
·
Tristan Manalac
Approvals
Denali Delivers ‘Welcome Positive’ for Rare Disease Space With FDA’s Hunter Syndrome Nod
March 26, 2026
·
3 min read
·
Tristan Manalac